News - Astellas Pharma, Genito-urinary

Filter

Popular Filters

Netherlands first to approve Astellas' Vesomni

23-05-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says that the Dutch Medicines…

Astellas PharmaEuropeGenito-urinaryPharmaceuticalRegulationVesomni

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Astellas' Betmiga Oked in EU for overactive bladder

14-01-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

Astellas links with KEK on tropical diseases; Upgraded by CS analysts

25-09-2012

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with the High Energy…

Astellas PharmaFinancialGenito-urinaryMyrbetriqOncologyPharmaceuticalResearchTropical diseasesXtandi

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

FDA approves Astellas' Myrbetriq for overactive bladder

02-07-2012

The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

New data support efficacy of Astellas' mirabegron for overactive bladder

28-02-2012

Astellas Pharma has reported the results of three separate clinical trials which further support the…

Astellas PharmaBetanisGenito-urinaryHomemirabegronPharmaceuticalVESIcare

Back to top